VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
HURA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HURATuHURA Biosciences, Inc.
$1.37$87M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HURA logo

TuHURA Biosciences, Inc.

HURA
NASDAQ · Oncology Biotech
$1.37
At close - Nov 18, 4:00 PM EST - USD
Market Cap$87M
P/E-3.0x
52W High$3.43
Volume193.38K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Clinical Development Costs Threaten Liquidity Runway Stability

TuHURA Biosciences remains a high-risk, pre-revenue entity whose financial viability is entirely contingent upon the successful execution of Phase 3 clinical trials.

GrowthContracting
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

HURA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-105% Peers

P/E is 105% below peer median

03

Market leadership

RS 33 · Lag

Laggard (Underperforming 67% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 13

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
HURA+82.79%
S&P 500 (^GSPC)+6.88%
1-Year Return
HURA-29.02%
S&P 500 (^GSPC)+10.62%
3-Year Return
HURA-89.27%
S&P 500 (^GSPC)+59.54%
5-Year Return
HURA-96.49%
S&P 500 (^GSPC)+57.34%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$30M-38.6% YoY
Free cash flow FY25
-$28M-87.4% YoY
Operating margin FY25
-
ROIC (FY25)-236.7%
Avg ROIC 5Y-236.7%
ROE (TTM)-146.8%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (45%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 13, 2026
-$0.10+27.5%
vs -$0.14
—
vs —
Q3 2026
Aug 13, 2026
-$0.14+8.7%
vs -$0.15
—
vs —
Q2 2026
May 15, 2026
-$0.13-8.3%
vs -$0.12
—
vs —
Q2 2026
Mar 31, 2026
-$0.13-1.4%
vs -$0.12
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
PRNewsWire·5d ago
TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

TAMPA, Fla., Nov. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's third quarter ended September 30, 2026, and provided a corporate update.

PRNewsWire·Nov 4, 2026
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition

Presentations highlight the role of the Delta Opioid Receptor (DOR) as a novel target central to the regulation of multiple genes involved in immune suppression, chemotaxis and proliferation of immune suppressing cells in cancer and autoimmune disease including MDSCs, T regs, and M2 macrophages TAMPA, Fla., Nov. 4, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it would present three posters on its research on the role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of Myeloid-Derived Suppressor Cells (MDSCs) at the upcoming 68th American Society of Hematology (ASH) Annual Meeting and Exposition taking place on December 12-15, 2026, in New Orleans, Louisiana.

MarketBeat·Oct 26, 2026
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study

TuHURA Biosciences NASDAQ: HURA presented preliminary results from its ongoing open-label Phase 1b study of IFx-2.0 in patients with metastatic Merkel cell carcinoma, or MCC, reporting confirmed partial responses in the first three evaluable patients treated in the frontline setting.

PRNewsWire·Oct 26, 2026
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma

Preliminary results demonstrate major objective tumor responses in first 3 patients at 6 months  Company to host a webcast today, October 26, 2026, at 8:30 am ET TAMPA, Fla., Oct. 26, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy to Keytruda® in first-line treatment of metastatic Merkel Cell Carcinoma (MCC).

Filtered for TuHURA Biosciences, Inc.More Headlines
04

Compare before deciding

Benchmark HURA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for TuHURA Biosciences, Inc. (HURA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
HURA logoHURATuHURA Biosciences, Inc.Current
$1.37$87.25M-2.97——-146.8%0.01%
IMVT logoIMVTImmunovant, Inc.
$33.17$6.85B-13.47—-7173.52%-63.01%—
KYMR logoKYMRKymera Therapeutics, Inc.
$121.13$9.96B-34.69-16.72%-341.87%-22.39%—
RCUS logoRCUSArcus Biosciences, Inc.
$15.76$1.98B-4.51-4.26%-445%-90.04%—
TGTX logoTGTXTG Therapeutics, Inc.
$66.12$10.12B97.2187.32%11.81%17.62%—
AGEN logoAGENAgenus Inc.
$6.40$266.51M18.9710.37%20.98%——

Compare HURA vs Peers

TuHURA Biosciences, Inc. (HURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for HURA.

Scale Benchmark

vs MRK

Larger-name benchmark to compare HURA against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, KYMR, RCUS, TGTX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

HURA SEC Filings & Documents

TuHURA Biosciences, Inc. (HURA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 13, 2026·SEC

Material company update

Nov 6, 2026·SEC

Material company update

Aug 21, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 31, 2026·SEC

FY 2025

Mar 31, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 13, 2026·SEC

FY 2026

Aug 14, 2026·SEC

FY 2026

May 15, 2026·SEC

Get notified when HURA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

HURA Frequently Asked Questions

TuHURA Biosciences, Inc. (HURA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is HURA profitable?

No. TuHURA Biosciences, Inc. (HURA) reported a net loss of $29.9M over the trailing twelve months.

Dividend & Returns
Does HURA pay dividends?

TuHURA Biosciences, Inc. (HURA) does not currently pay a meaningful dividend.

What is HURA's return on equity?

TuHURA Biosciences, Inc. (HURA) had a return on equity (ROE) of -146.8% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is TuHURA Biosciences, Inc.'s free cash flow?

TuHURA Biosciences, Inc. (HURA) had negative free cash flow of $23.8M over the trailing twelve months.

What if you invested $1,000 in HURA back in 2014?

Total return calculator · dividends reinvested · 12+ years of data

See returns →